AMDL Confirms Special Shareholders Meeting in September
July 27 2006 - 4:18PM
PR Newswire (US)
TUSTIN, Calif., July 27 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), developer and marketer of tests for the early detection
of cancer and other serious diseases, today said that a shareholder
notice and proxy statement is being mailed this week to
shareholders regarding a Special Meeting to be held on September 8,
2006, at 10 a.m. at the Hyatt Regency Hotel, 17900 Jamboree Road,
Irvine, California. The proxy statement asks shareholders to
approve the Stock Purchase and Sales Agreement for the acquisition
of 100 percent of the outstanding capital stock of Jade
Pharmaceutical Inc. The proxy also asks shareholders to vote on
members of the Board of Directors and other related items. AMDL's
Board of Directors has unanimously approved the acquisition of Jade
Pharmaceutical but the transaction cannot be completed without
shareholder approval. Jade Pharmaceutical is the owner of Jiangxi
Jade Bio-Chem Pharmacy Company Ltd. and Yanbian Yiqiao Bio-Chem
Pharmacy Company Ltd. in the People's Republic of China. "I
encourage all shareholders to vote in favor of this transaction. It
should be remembered that not voting is the same as a no vote,"
said Gary L. Dreher, AMDL CEO. "We urge shareholders to read the
proxy statement thoroughly and to contact us if they have any
questions." AMDL has filed with the Securities and Exchange
Commission a definitive proxy statement which it expects to mail to
shareholders of record on or after July 28, 2006, and other
relevant documents in connection with the shareholder approval of
the Jade Pharmaceutical acquisition and other matters to be put
before the shareholders of the Company. Investors and security
holders are advised to read the definitive proxy statement because
it contains important information. Investors and shareholders may
obtain a free copy of the definitive proxy statement and other
documents filed by AMDL at the Securities and Exchange Commission's
web site at http://www.sec.gov/. The definitive proxy statement and
such other documents may also be obtained from AMDL by directing
such request to AMDL, 2492 Walnut Ave., Suite 100, Tustin, CA
92780-6953, Attention: Investor Relations. A description of any
interests that the Company's directors and executive officers have
in the matters presented to AMDL shareholders is available in the
definitive proxy statement. About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, is a theranostics company,
involved in the detection and treatment of the same disease,
cancer. AMDL is the inventor, developer and worldwide marketer
through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdl.com/. SAFE HARBOR This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024